Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland

European Journal of Cancer Prevention

Volumn 24, Issue 4, 2015, Pages 296-304

  Basavaraju, Umesh ^a   Shebl, Fatma M ^b   Palmer, Andrew J ^a   Berry, Susan ^a   Hold, Georgina L ^a   El Omar, Emad M ^a   Rabkin, Charles S ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

colorectal neoplasia; cytokine; polymorphisms; screening

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CYCLOOXYGENASE 2; IL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL1RN PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PTGS2 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADENOMATOUS POLYP; ADULT; AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CASE CONTROL STUDY; COLONOSCOPY; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; ADENOMA; CARCINOMA; COHORT ANALYSIS; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MIDDLE AGED; OCCULT BLOOD; SCOTLAND;

ADENOMA; AGED; C-REACTIVE PROTEIN; CARCINOMA; CASE-CONTROL STUDIES; COHORT STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYTOKINES; EARLY DETECTION OF CANCER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-4; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; OCCULT BLOOD; POLYMORPHISM, GENETIC; SCOTLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930754943     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000087     Document Type: Article

References (46)

1. Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27:2217-2224.
2. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010). C-reactive protein and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 102:202-206.
3. Austin PC (2011). Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150-161.
4. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. CAPP2 Investigators (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2801-2807.
5. Cacev T, Jokic M, Loncar B, Krizanac S, Kapitanovic S (2010). Interleukin-6-174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol 29:177-182.
6. Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, et al. (2006). Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1674-1687.
7. Chan AT, Ogino S, Giovannucci EL, Fuchs CS (2011a). Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140:799-808.
8. Chan AT, Ogino S, Giovannucci EL, Fuchs CS (2011b). Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140 (no. 3):799-808.
9. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al. (2007). NCI-NHGRI Working Group on Replication in Association Studies. Nature 447:655-660.
10. Chiu HM, Lin JT, Chen TH, Lee YC, Chiu YH, Liang JT, et al. (2008). Elevation of C-reactive protein level is associated with synchronous and advanced col-orectal neoplasm in men. Am J Gastroenterol 103:2317-2325.
11. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. (2003). Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124:1193-1201.
12. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402.
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
14. Gorouhi F, Islami F, Bahrami H, Kamangar F (2008). Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 98:1443-1451.
15. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006). Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126-1131.
16. Gunter MJ, Cross AJ, Huang WY, Stanczyk FZ, Purdue M, Xue X, et al. (2011). A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Biomarkers Prev 20:537-544.
17. Heikkilä K, Ebrahim S, Lawlor DA (2008). Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44:937-945.
18. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. (2009). Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15-26.
19. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007). Screening for col-orectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 24:CD001216.
20. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004). Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700.
21. Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M, Ozasa K, et al. (2005). Coloretal cancer and serum C-reactive protein levels: a case-control study nested in the JACC study. J Epidemiol 15 (Suppl 2):S185-S189.
22. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. (2008). Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 68:323-328.
23. Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Colman H, Le Neel T, et al. (2008). Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. BMC Cancer 8:326.
24. Kushner I, Rzewnicki DL (1994). The acute phase response: general aspects. Baillieres Clin Rheumatol 3:513-530.
25. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, et al. (2003). Association of common polymorphisms in inflammatory genes interleukin (IL) 6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63:3560-3566.
26. Li M, You Q, Wang X (2011). Association between polymorphism of tumor necrosis factor alpha-308 gene promoter and colon cancer in Chinese population. Genet Test Mol Biomarkers 15:743-747.
27. Liu S, Tinker L, Song Y, Rifai N, Bonds DE, Cook NR, et al. (2007). A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 167:1676-1685.
28. Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM (2005). The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14:1613-1618.
29. Masson LF, McNeill G, Tomany JO, Simpson JA, Peace HS, Wei L, et al. (2003). Statistical approaches for assessing the relative validity of a food-frequency questionnaire: use of correlation coefficients and the kappa statistic. Public Health Nutr 3:313-321.
30. Menter DG, Schilsky RL, DuBois RN (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16:1384-1390.
31. Ognjanovic S, Yamamoto J, Saltzman B, Franke A, Ognjanovic M, Yokochi L, et al. (2010). Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control. 21:. pp. 1131-1138.
32. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Japan Public Health Center-Based Prospective Study Group (2006). Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 15 (no. 4):690-695.
33. Pereira C, Medeiros RM, Dinis-Ribeiro MJ (2009). Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 21:76-91.
34. Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011). Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 20:297-307.
35. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41.
36. Sansbury LB, Bergen AW, Wanke KL, Yu B, Caporaso NE, Chatterjee N, et al. (2006). Inflammatory cytokine gene polymorphisms, non-steroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial. Cancer Epidemiol Biomarkers Prev 15:494-501.
37. Siemes C, Visser LE, Coebergh JW, Splinter TAW, Witteman JCM, Uitterlinden AG, et al. (2006). C-reactive protein levels, variation in the c-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol 24:5216-5222.
38. Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD (2007). IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18:1095-1105.
39. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW (1993). Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91:403-404.
40. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, et al. (2006). Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12:5037-5043.
41. Trinchieri G (2011). Innate inflammation and cancer: is it time for cancer prevention? F1000 Med Rep 3:11.
42. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA (2008a). C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123 (no. 5):1133-1140.
43. Tsilidis KK, Erlinger TP, Rifai N, Hoffman S, Hoffman-Bolton J, Helzlsouer KJ, Platz EA (2008b). C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 19:559-567.
44. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. (2009). Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 20:. pp. 1739-1751.
45. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J (2005). PTGS2 (COX-2)-765G < C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616-619.
46. Viet HT, Wågsäter D, Hugander A, Dimberg J (2005). Interleukin-1 receptor antagonist gene polymorphism in human colorectal cancer. Oncol Rep 14:915-918.